During the investigation of the effects of hypotensive agents on the pulmonary circulation in mitral stenosis, an unexpected result was observed following the administration of 1-hydrazinophthalazine (apresoline). It was found that in patients with mitral stenosis, this drug caused elevation of the pulmonary arterial pressure, while reducing the systemic arterial pressure. This effect of l-hydrazinophthalazine may be of considerable importance in the treatment of hypertension associated with mitral disease.
Total pulmonary resistance was calculated from the formula:
Resistance (dynes/sec./CM._5)mean pulmonary arterial pressure (mm.Hg) x 1332 cardiac output (ml./sec.) It is realized that the validity of this procedure is not beyond question because it may not be accurate in the presence of vasomotor changes or turbulent flow across a stenosed valve: it has been used only as a rough index.
RESULTS
A typical result is shown in Fig. 1 Table I . The pulse rate rose in the 9 subjects in whom it was measured. The cardiac output also rose in all cases, though the increase was small, and of doubtful significance, in three. The increases in heart rate and in pulmonary artery pressure pressure (Fig. 2) . Subjects with a high control level showed a greater increase than those in whom the basal level was low. In this and subsequent figures the closed circles represent patients with mitral disease, and the open circles represent the values obtained in the two hypertensive subjects. In one of the hypertensives there was a fall in pulmonary arterial pressure with a large fall in systemic blood pressure. In the other the rise in pulmonary artery pressure was much smaller than that observed in the mitral patients with comparable pulmonary arterial pressures. In both cases the cardiac output rose after 1-hydrazinophthalazine; the pulse rate also increased but the rise was less than in the patients with mitral disease. DIsCUSSION The principal factors that may be concerned in the rise of pulmonary arterial pressure are pulmonary vasoconstriction, increase in cardiac output, and increase in pulse rate. In the absence of information about changes in the pulmonary " capillary " pressure, the part played by possible constriction of the pulmonary arterioles cannot be assessed. The development of incipient pulmonary cedema in two subjects suggests that, in them at least, the pulmonary " capillary " pressure rose following the administration of the drug. If pressure in mitral stenosis during exercise, which were not prevented by increased pulmonary vascular (arteriolar) resistance. Cardiac output was increased in all our subjects, though the increase was very small in three. In normal subjects undertaking exercise the pulmonary artery pressure does not rise above the upper limit of normal until the flow exceeds approximately three times the basal flow (Cournand, 1950) . This implies that vasodilatation occurs in the pulmonary system of normal subjects with exercise. In mitral stenosis the capacity to tolerate an increased cardiac output is impaired, so that, even where there is little or no pulmonary hypertension at rest, a moderate degree of effort commonly causes a distinct rise in pulmonary arterial pressure. In Fig. 3 the percentage increase in cardiac output in our cases is plotted against the percentage increase in pulmonary arterial pressure. There is no relationship between the two variables (r= +0'132, p>010). This argues against the pressure rise being simply a manifestation of increased flow through a relatively inflexible pulmonary vascular system, although the increased output probably plays a part in some cases. It is also evident from Table I that a high initial pressure or resistance is not necessarily associated with inability to raise the cardiac output in response to administration of 1-hydrazinophthalazine.
It is probable that in mitral stenosis the whole period of diastole following the opening of the mitral valve is taken up with inflow into the ventricle (Wiggers, 1923) . This contrasts with the state of affairs in normal subjects, in whom most of the ventricular filling takes place early in diastole. Increase in pulse rate from 80 to 140 may shorten the duration of diastole by as much as 12 seconds each minute (Gorlin et al., 1951) . In mitral stenosis in such circumstances cardiac output can only be maintained or augmented by increasing the rate of flow through the valve during diastole; this in turn means that the pressure gradient across the valve must increase, so that back pressure develops in the pulmonary vascular system. In this series the increase in pulse rate at the time of 42g group.bmj.com on June 24, 2017 -Published by http://heart.bmj.com/ Downloaded from maximal pulmonary arterial pressure was significantly related to the rise in pulmonary arterial pressure (r= +0-761, p<002). Tachycardia may not be the whole explanation for the pressure rise, because in some subjects the tachycardia lasted rather longer than the rise in pulmonary artery pressure. The degree of tachycardia was noticeably less in the two cases of hypertension. The response was not related to the type of rhythm, and it is interesting to observe that the increase in heart rate in subjects with atrial fibrillation was similar to the rise in subjects in sinus rhythm. The hypertensive effect of 1-hydrazinophthalazine on the pulmonary circulation of subjects with mitral disease is probably the result of the interaction of several factors, of which the most important seem to be the degree of initial pulmonary hypertension and the degree of tachycardia following the administration of the drug. It has been stated that the incidence of hypertension in mitral stenosis is not significantly different from that in a control hospital population (Gray, 1954) , and in a few instances, hypertension may be the cause of death.
The results of this investigation suggest that the use of l-hydrazinophthalazine is contraindicated in mitral disease, as it raises cardiac rate and output and pulmonary arterial pressure, so increasing the load on the right ventricle. It may predispose towards the development of pulmonary cedema.
SUMMARY
Administration of 1-hydrazinophthalazine to ten patients with mitral disease was followed by elevation of the pulmonary arterial pressure, increased pulse rate and cardiac output, and fall in systemic blood pressure.
It is suggested that 1-hydrazinophthalazine should not be used in the treatment of hypertension associated with mitral disease, as it is likely to increase the load on the right ventricle, and may even cause pulmonary cedema.
